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ABSTRACT
Background Immunotherapy represents the future of 
clinical cancer treatment. The type of cancer cell death 
determines the antitumor immune response and thereby 
contributes to the efficacy of anticancer therapy and 
long- term survival of patients. Induction of immunogenic 
apoptosis or necroptosis in cancer cells does activate 
antitumor immunity, but resistance to these cell death 
modalities is common. Therefore, it is of great importance 
to find other ways to kill tumor cells. Recently, ferroptosis 
has been identified as a novel, iron- dependent form of 
regulated cell death but whether ferroptotic cancer cells 
are immunogenic is unknown.
Methods Ferroptotic cell death in murine fibrosarcoma 
MCA205 or glioma GL261 cells was induced by RAS- 
selective lethal 3 and ferroptosis was analyzed by 
flow cytometry, atomic force and confocal microscopy. 
ATP and high- mobility group box 1 (HMGB1) release 
were detected by luminescence and ELISA assays, 
respectively. Immunogenicity in vitro was analyzed by 
coculturing of ferroptotic cancer cells with bone- marrow 
derived dendritic cells (BMDCs) and rate of phagocytosis 
and activation/maturation of BMDCs (CD11c+CD86+, 
CD11c+CD40+, CD11c+MHCII+, IL-6, RNAseq analysis). 
The tumor prophylactic vaccination model in immune- 
competent and immune compromised (Rag-2−/−) mice was 
used to analyze ferroptosis immunogenicity.
Results Ferroptosis can be induced in cancer cells by 
inhibition of glutathione peroxidase 4, as evidenced by 
confocal and atomic force microscopy and inhibitors’ 
analysis. We demonstrate for the first time that ferroptosis 
is immunogenic in vitro and in vivo. Early, but not late, 
ferroptotic cells promote the phenotypic maturation of 
BMDCs and elicit a vaccination- like effect in immune- 
competent mice but not in Rag-2−/− mice, suggesting that 
the mechanism of immunogenicity is very tightly regulated 
by the adaptive immune system and is time dependent. 
Also, ATP and HMGB1, the best- characterized damage- 
associated molecular patterns involved in immunogenic 
cell death, have proven to be passively released along 
the timeline of ferroptosis and act as immunogenic signal 
associated with the immunogenicity of early ferroptotic 
cancer cells.
Conclusions These results pave the way for the 
development of new therapeutic strategies for cancers 
based on induction of ferroptosis, and thus broadens the 
current concept of immunogenic cell death and opens 
the door for the development of new strategies in cancer 
immunotherapy.
INTRODUCTION
Immunotherapy has emerged as an inde-
pendent and effective antineoplastic strategy 
alongside surgery, radiotherapy and chemo-
therapy.1 Immunogenic cell death (ICD) has 
recently been recognized as a critical determi-
nant of the efficacy of cancer therapy.2–7 The 
ICD concept combines the ability to effec-
tively kill cancer cells with the activation of an 
immune response specific for the cancer cells 
and leading to a strong and longlasting anti-
cancer immunity. ICD- inducing agents elicit 
activation of a danger pathway involving the 
emission of ICD mediators known as damage- 
associated molecular patterns (DAMPs). 
DAMPs constitute a family of endogenous 
molecules that acquire immunostimulatory 
properties when exposed on the outer cell 
membrane or released in the extracellular 
matrix in a defined spatial–temporal manner. 
They include ATP, high- mobility group box 1 
(HMGB1), calreticulin (CRT) and proinflam-
matory cytokines such as type I interferons 
(IFNs).8–12 When mobilized, DAMPs act as 
danger signals and as adjuvant molecules to 
activate the immune system.2 7 13
Initially, the ICD concept was described 
for cancer cells undergoing apoptosis.11 14–16 
However, evasion of apoptosis is in itself a 
hallmark of cancer and can abolish the cell 
death response, which often leads to the 
development of apoptosis resistance.17 18 The 
discovery of other forms of regulated cell 
death paved the way for the development 
of alternative strategies for cell death induc-
tion. For example, necroptosis is transduced 
by receptor- interacting protein kinase-1 
(RIPK-1), RIPK-3 and a mixed lineage kinase 
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domain- like pseudokinase triggering necroptosis. Induc-
tion of necroptosis has become of utmost importance in 
experimental cancer therapy as an alternative strategy 
to apoptosis.19–21 It was recently reported that necro-
ptotic cancer cells could be proinflammatory and immu-
nogenic.22–24 Although the induction of immunogenic 
necroptosis in cancer cells seems to be promising in terms 
of activating antitumor immunity in experimental mouse 
models, it is important to stress that many cancers often 
develop necroptosis resistance.25–27 Therefore, triggering 
immunogenic apoptosis or necroptosis would not always 
be the optimal strategy. It is of great importance to find 
novel ways to kill tumor cells by triggering cell death 
modalities other than apoptosis and necroptosis. Ferro-
ptosis is an iron- dependent cell death type and it can be 
selectively triggered in cells expressing oncogenic mutants 
of RAS.28 Oxidized phosphatidylethanolamines are crucial 
for ferroptosis execution, and ferroptosis can be induced 
by blocking the xc cystine/glutamate antiporter system or 
glutathione peroxidase 4 (GPX4), resulting in a defective 
GSH- redox system.28–30 Thus, in addition to apoptosis and 
necroptosis, ferroptosis might be another option to over-
come cell death resistance and enhance the efficacy of anti-
cancer therapy. Although the concept of ferroptosis- based 
cancer therapy is novel and provides potentially promising 
pharmacological strategy,31–35 whether ferroptotic cancer 
cells are immunogenic is currently unknown.
In this study, we assessed the immunogenicity of ferro-
ptotic cancer cells in vitro and in vivo and tested their 
potential as an alternative approach to cancer immuno-
therapy. We found that early ferroptotic cancer cells were 
efficiently engulfed by bone marrow- derived dendritic 
cells (BMDCs) and were able to promote BMDCs matura-
tion and activation. However, late ferroptotic cancer cells 
were not immunogenic, as indicated by the percentage of 
BMDCs expressing major histocompatibility complex class 
II (MHCII) and CD80 and CD86 markers and by the levels 
of IL-6 as well as by RNAseq analysis. Moreover, in vitro 
data were confirmed in vivo by showing the effective vacci-
nation activity of early ferroptotic cancer cells in a tumor 
prophylactic vaccination model in immune- competent 
mice but not in immune compromised Rag-2−/− mice. 
Importantly, the protective vaccination effect of the early 
ferroptotic cells was maximal but was absent in the late 
ferroptotic cancer cells. Moreover, ATP and HMGB1, the 
best- characterized DAMPs involved in ICD, have proven 
to be passively released along the timeline of ferroptosis 
and act as immunogenic signals associated with the immu-
nogenicity of early ferroptotic cancer cells. These findings 
identify ferroptotic cancer cells in the early death stages 
as effective inducers of an adaptive immune response and 
open the door for the development of new strategies based 
on ferroptotic cell vaccination for cancer immunotherapy.
MATERIALS AND METHODS
Cell lines and cell culture
Murine fibrosarcoma MCA205 and murine glioma GL261 
cells were cultured in Roswell Park Memorial Institute 
(RPMI) 1640 (Gibco) containing 2 g/L glucose. In addi-
tion, the RPMI medium was supplemented with L- gluta-
mine (Gibco, 2 mM), heat- inactivated fetal bovine serum 
(FBS, Fisher Scientific, 10%), penicillin (100 U/mL) and 
streptomycin (Gibco, 100 µg/L). Murine glioma GL261 
cells were cultured in Dulbecco's Modified Eagle Medium 
(DMEM) (Gibco) containing glucose (4.5 g/L) and 
supplemented with 10% heat- inactivated FBS, sodium 
pyruvate (Sigma Aldrich, 100 µM), penicillin (100 U/
mL) and streptomycin (100 µg/L). All cells were main-
tained at 37°C under 5% CO2.
Cell death assay and inhibitor analysis by multimode 
microplate reader
MCA205 or GL261 cells were seeded at 105 cells/well 
in a 96- well plate. After incubation overnight, the cells 
were stained with 3.3 µM Sytox Green nucleic acid stain 
(molecular probes) and stimulated with 2.5 µM RAS- 
selective lethal 3 (RSL3) (Sigma Aldrich) for different 
durations (1, 3, 6 and 24 hours). Cell death was analyzed 
as described in Demuynck et al.36 Fluorescence was 
measured on a Tecan Spark 20M multimode microplate 
reader.
The following inhibitors were used to block different 
cell death modalities36 37: the pan- caspase inhib-
itor carbobenzoxy- valyl- alanyl- aspartyl- (O- methyl)- 
fluoromethylketone (zVAD- fmk, 25 µM, apoptosis, 
Bachem), the inhibitor of ROS and lipid peroxidation 
ferrostatin-1 (Fer-1, 1 µM, ferroptosis, Sigma Aldrich), the 
iron chelator deferoxamine (DFO, 10 µM, ferroptosis, 
Sigma Aldrich), the nonspecific lipophilic antioxidant 
α-tocopherol (α-toc, 100 µM, ferroptosis, Sigma Aldrich) 
and the RIPK-1 inhibitor necrostatin- 1s (Nec- 1s, 20 µM, 
necroptosis, Abcam). The cell death inhibitors were 
added 1 hour before RSL3 stimulation.
For recovery experiments on both MCA205 and GL261 
cells, after treatment for 1, 3 or 6 hours, RSL3- conditioned 
medium (2.5 µM RSL3) was replaced with drug- free 
medium; cell death was determined 24 hours after RSL3 
stimulation as described above.
Cell death assay by flow cytometry
The cells were washed in Annexin- V binding buffer 
(10 mM Hepes, pH 7.4, 0.14 mM NaCl and 2.5 mM CaCl2), 
followed by staining with Sytox Blue Nucleic Acid Stain 
(molecular probes, S11348) and Annexin- V, Alexa Fluor 
488 conjugate (molecular probes, A13201). The cells 
were run on a Becton Dickinson Fluorescence - Activated 
Cell Sorting (BD FACS) Canto flow cytometer, and the 
data were analyzed by using FlowJo software (V.10.0.8).
Live-cell imaging
Cells were seeded at 5.5×104 cells/mL of complete 
growth medium (DMEM) in a surface- treated 35 mm 
confocal dish (Van Waters and Rogers (VWR), cat- no: 
75 856–740) 1 day before the experiments. Cell death 
was induced just before imaging, nuclei were visualized 
using Hoechst 33 342 (1 µM, Thermo Fisher) and cell 
G
eneeskunde - P






















3Efimova I, et al. J Immunother Cancer 2020;8:e001369. doi:10.1136/jitc-2020-001369
Open access
death was monitored by propidium iodide (PI) exclusion 
(1 µM, Thermo Fisher). Live- cell imaging was performed 
on a Nikon A1R confocal microscope (Nikon) using a 
Chromatic Aberration Free Infinity (CFI) S Plan Fluor 
Extra- Long Working Distance (ELWD) 40XC air objec-
tive. Images were acquired sequentially every 2 min. From 
each image stack, montages of the multi- tiff time series 
and three- channel overlays (brightfield, Hoechst 33342, 
PI) were made using ImageJ 1.49 m, a public domain 
imaging software.
Morphological analysis by atomic force microscopy
The MCA205 cells were seeded 1 day before the exper-
iments in glass- bottom Petri dishes (VWR, cat- no: 
75 856–740) at a density of 5.5×104 cells/mL. The atomic 
force microscopy (AFM) instrument used to acquire the 
images was NanoWizard 4 (Bio- AFM, JPK/Bruker). Topo-
graphical images were acquired in the JPK QI mode using 
ATEC- CONT cantilevers. These sharp- tipped cantilevers 
(radius of curvature <10 nm) have a larger tip height 
(15 µm) to avoid contact of the cantilever beam with the 
cells during imaging. Before topographical imaging, the 
cells were fixed before induction, and 1 hour and 2 hour 
postinduction. These timepoints were determined based 
on confocal laser scanning microscopy images. At these 
timepoints, the cells showed interesting morphological 
changes: normal (control) morphology before induc-
tion, rounding of ferroptotic cells after 1 hour and plasma 
membrane permeabilization as indicated by PI exposure 
after 2 hours. First, the dishes were washed three times 
with phosphate- buffered saline (PBS) and then a 4% para-
formaldehyde solution (PFA, Alfa Aesar, 043368.9M) was 
added for 10 min. Finally, the paraformaldehyde solution 
was replaced with PBS, and between measurements, the 
cells were stored at 4°C. Representative height images of 
the cells at the aforementioned timepoints were obtained.
Quantification of ATP release
Fibrosarcoma MCA205 cells were seeded and treated with 
RSL3 as described above. Mitoxantrone (MTX, 2 µM, 
Sigma Aldrich) was used as a positive control. After treat-
ment, the cells were incubated for 0.5, 1, 6 and 24 hours 
in medium with 2% FBS. At each timepoint, superna-
tants were collected and centrifuged at 15 000 rpm at 
4°C for 3 min. They were either stored at –80°C or used 
immediately for ATP measurement. ATP was quantified 
using CellTiter- Glo Luminescent Cell Viability Assay kit 
(Promega, G7571), as described by the manufacturer. 
Luminescence was measured on a Tecan Spark 20M 
multimode microplate reader.
ATP release was also analyzed in the supernatants 
after 3 hours and 24 hours of cocultivation of BMDCs 
with MCA205 cells (ratio 1:5). For this analysis, MCA205 
cells were pre- treated for 1, 3, or 24 hours with 2.5 µM of 
RSL3 or for 24 hours with 2 µM MTX. Controls were left 
untreated. BMDCs and MCA205 cocultivation and ATP 
measurement were performed as described above.
Quantification of HMGB1 release
MCA205 cells were induced with 2.5 µM RSL3 for 1, 3 
or 24 hours or with 2 µM MTX (Sigma Aldrich, used as a 
positive control). After treatment, the supernatants were 
collected, cleared by centrifugation and frozen at −20°C 
for later HMGB1 quantification with an ELISA kit (IBL- 
Hamburg). All assays were performed in accordance with 
the respective manufacturers’ instructions and HMGB1 
was quantified using Tecan Spark 20M multimode 
microplate reader. The data were analyzed with a four- 
parameter logistic curve fit.
HMGB1 release was also analyzed in the superna-
tants after 1, 3 and 24 hours of coculture of BMDCs with 
MCA205 cells (ratio 1:5). For this analysis, MCA205 
cells were pretreated for 1, 3 or 24 hours with 2.5 µM of 
RSL3 or for 24 hours with 2 µM MTX. Controls were left 
untreated. BMDCs and MCA205 coculture and HMGB1 
measurement were performed as described.
Generation of mouse BMDCs
BMDCs were harvested from the femurs and tibias of 
C57BL/6 J mice (age 7–10 weeks) and differentiated 
for 9 days using RPMI 1640 medium supplemented with 
5% heat- inactivated FBS, 20 ng/mL mouse granulocyte 
macrophage colony stimulating factor (VIB Protein Core, 
IRC- UGent, Ghent, Belgium), 1% L- glutamine, 1 mM 
sodium pyruvate, 50 µM β-mercaptoethanol, 100 U/
mL penicillin and 100 µg/L streptomycin. The culture 
medium was refreshed on days 3 and 6.
Phagocytosis assay
Target fibrosarcoma MCA205 cells were either left 
untreated (control, live cells) or induced to die by stim-
ulation with 2.5 µM of RSL3 for 1 hour or 24 hours. The 
cells were collected, washed and labeled with 20 ng of 
pHrodo iFL Green STP Ester (Thermo Fisher, P36012) 
per 106 cells in PBS for 30 min. They were then washed and 
cocultured with BMDCs at ratio of 1:1 or 1:5 for 2 hours. 
Afterward, the cocultured cells were harvested, incubated 
with a mouse Fc block (eBioscience, 16016185), immu-
nostained with phycoerythrin (Pe)- Cy7- anti- CD11c (BD 
PharMingen, 561022) and analyzed by a BD FACSCanto 
flow cytometer. The FlowJo software (V.10.0.8) was used 
for the flow cytometry data analysis. True engulfment of 
pHrodo- labeled dead cells by BMDCs was calculated based 
on a gating strategy that allows analysis of only single cells. 
They were defined as CD11c+pHrodo+ double- positive 
cells. Importantly, before setting up the phagocytosis 
assay, the percentage of the target MCA205 cell death was 
always measured by flow cytometry as described in the 
section on cell death assay.
Analysis of the expression of BMDCs surface markers and 
IL-6 production
Cell death was induced in fibrosarcoma MCA205 cells by 
addition of MTX for 24 hours or RSL3 for 1 hour, 3 hours 
or 24 hours as described in the section on cell death assay. 
The dead MCA205 cells were collected, washed in RPMI 
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culture medium and cocultured with 25×104 BMDCs at a 
ratio of 1:5. The cells were cocultured for 24 hours at 37°C 
in six- well plates in 2 mL of RPMI culture medium. The 
BMDCs that were left untreated or stimulated with 20 ng/
mL lipopolysaccharide (LPS; Sigma Aldrich, L2630) 
were used as a control. After 24 hours of coculture, all 
the cells were harvested, spun down (200 × g for 5 min at 
4°C) and washed once in Dulbecco’s PBS (DPBS; Gibco). 
Maturation of BMDCs was analyzed by immunostaining 
with Pe- Cy7- anti- CD11c (BD PharMingen, 561022), 
FITC- anti- MHC class II (eBioscience, 11532282), eFluor 
450- anti- CD86 (eBioscience, 48086280), eFluor 450- 
anti- CD80 (eBioscience, 48080182) and mouse Fc block 
(eBioscience, 16016185). Mature BMDCs cells were iden-
tified as a percentage of CD11c+MHCII+, CD11c+CD80+ 
and CD11c+CD86+ cells. The BD FACS Canto II flow 
cytometer was used for sample acquisition and the data 
were analyzed with FlowJo software (V.10.0.8). Before the 
maturation assay, the percentage of death of the target 
MCA205 cells was always measured by flow cytometry as 
described in the section on cell death assay. After cocul-
turing BMDCs with the ferroptotic MCA205 cancer cells, 
the supernatants were collected and IL-6 was measured by 
ELISA (BioLegend).
RNA isolation and BMDCs enrichment after coculture with 
glioma GL261 cells
For the RNA sequencing analysis, there were three exper-
imental groups: BMDCs alone (a negative control), 
BMDCs cocultured for 6 hours with GL261 cells 
pretreated with either MTX (a positive control, 2 µM, 
24 hours) or RSL3 (2.5 µM, 24 hours). BMDCs isolated 
from four mice were used for each experimental group 
and were cocultured with GL261 cells in a ratio of 1:5. 
For the BMDCs cocultures with GL261 cells treated with 
RSL3 or MTX additional technical replicates have been 
included. After 6 hours of coculture, all the cells were 
harvested and washed once with DPBS. For the first step 
of BMDCs enrichment, Dead Cell Removal Kit (MACS 
Miltenyi Biotec) was used to remove the dead cells from 
the coculture. After that, the final eluate was loaded onto 
MS columns (MACS Miltenyi Biotec) and treated with the 
CD11c MicroBeads UltraPure kit (MACS Miltenyi Biotec) 
to enrich for CD11c+ BMDCs. The enrichment quality 
was measured by flow cytometry on a BD FACS Canto II 
flow cytometer. After enrichment/purification of CD11c+ 
cells, total RNA was extracted using RNeasy Mini Kit 
(QIAGEN). The quantity and integrity of the isolated 
RNA were analyzed with a NanoDrop 8000 spectropho-
tometer (Thermo Fisher) and a Fragment Analyser 5200 
system (Agilent), respectively. The purity of CD11c+ 
BMDCs after each step was tested on the BD FACS Canto 
II flow cytometer as described above.
RNAseq analysis
RNAseq library preparation was performed using the 
TruSeq Stranded mRNA kit (Illumina) according to 
the manufacturer protocol, followed by PE100 cycles 
sequencing on one lane of a NovaSeq 6000 S1 run (Illu-
mina). Gene expression values were determined using 
Kallisto. Limma- Voom was used for differential expres-
sion analysis, with Benjamini- Hochberg- based multiple 
testing correction.
Mice
Immune- competent C57BL/6 J mice and immune- 
compromised Rag-2-/- mice on C57BL/6 background 
(7–9 weeks old) were housed in specific pathogen- free 
conditions. The experiments were performed according 
to the guidelines of the local Ethics Committee of Ghent 
University.
In vivo prophylactic tumor vaccination
Death of MCA205 cells was induced in vitro by treatment 
with RSL3 for 24 hours or 3 hours, as described above. 
Next, the cells were harvested, washed once in DPBS 
and resuspended at a density 5×105 cells per 200 µL of 
DBPS. Mice were injected subcutaneously with 5×105 
ferroptotically dying MCA205 cells with or without the 
addition of 4 mg/kg oxiATP (adenosine 5′-diphosphate, 
periodate oxidized sodium salt, Sigma Aldrich) per 
mouse38 39 or with PBS. As a negative control, mice were 
vaccinated with 5×105 MCA205 cells subjected to freezing 
and thawing to cause accidental necrosis, which has been 
shown to be nonimmunogenic.22 40 On day 7 after vacci-
nation, the mice were challenged subcutaneously on the 
opposite flank with 1×105 viable MCA205 cells. In some 
experiments, mice were vaccinated with a half dose of 
ferroptotically dying MCA205 cells (2.5×105 cells) and on 
day 7 challenged on the opposite flank with 1×105 viable 
MCA205 cells. Tumor growth at the challenge site was 
monitored for up to 21 days after the challenge by using 
a caliper.
Statistical analysis
Statistics was calculated in GraphPad Prism (V.8.0.1). 
Cell death was analyzed by two- way Analysis of Variance 
(ANOVA) followed by Dunnett’s multiple comparisons 
test. The release of ATP in the coculture after 3 hours and 
24 hours was analyzed by two- way ANOVA. The results 
of the phagocytosis assay and the BMDCs activation and 
maturation assay were analyzed by two- way ANOVA with 
Tukey’s multiple comparisons test. Kaplan- Meier survival 
curves showing the timeline of tumor development were 
analyzed by log- rank Mantel- Cox test. Linear correlation 
between markers of phenotypic BMDCs maturation and 
cell death (Annexin V+ Sytox+ cells) was calculated by 
linear regression. We have chosen a 95% CI and all data 
showed p<0.001.
RESULTS
GPX4 inhibition induces ferroptosis in cancer cells
First, we examined the possibility of inducing ferroptotic 
cell death by inhibiting GPX4 in murine fibrosarcoma 
MCA205 cells. Cell death was evident at an early timepoint 
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(3 hours of stimulation with 2.5 µM of RSL3) and maximal 
after 24 hours of induction, when almost all the cells were 
dead (figure 1A). Phase- contrast and confocal fluorescent 
microscopy (figure 1B, online supplemental movie S1) 
revealed cell rounding, swelling and plasma membrane 
permeabilization, typical hallmarks of necrotic cell death. 
AFM further showed the appearance of uniform circular 
protrusions on the surface of ferroptotic cancer MCA205 
cells ranging from 1 to 5 µm after 1 hour of stimulation 
with RSL3 (figure 1C). These morphological irregulari-
ties during ferroptosis are in agreement with the previ-
ously described AFM features of ferroptotic cancer cells41 
as well as with confocal microscopic findings.42
To identify the type of cell death induced by RSL3 in 
MCA205 cells, specific cell death inhibitors were used 
to block apoptosis (zVAD- fmk, a pan- caspase blocker), 
necroptosis (Nec- 1s, a RIPK-1 inhibitor) or ferroptosis 
(DFO), an iron chelator, ferrostatin-1, an inhibitor of 
reactive oxygen species and lipid peroxidation and α-toc, 
a type of vitamin E).36 43 Importantly, the cell death 
induced by RSL3 was significantly blocked by the ferro-
ptosis inhibitors ferrostatin-1, DFO and α-toc but not by 
the pan- caspase inhibitor zVAD- fmk or the RIPK-1 inhib-
itor Nec- 1s (figure 1A). These results indicate that inhi-
bition of GPX4 in fibrosarcoma MCA205 cells leads to 
induction of purely ferroptotic cancer cell death.
Late ferroptotic cancer cells are phagocytosed but do not 
induce maturation of BMDCs
After 24 hours of stimulation with RSL3, 90% of MCA205 
cells were double positive for Annexin- V/Sytox Blue 
staining (figure 2A) and were thus in the late stage of ferro-
ptosis. Therefore, we tested the immunogenic properties 
of late ferroptotic cancer cells in vitro. By coculturing 
primary BMDCs with untreated ferroptotic cells (viable 
MCA205 cells) or cells treated for 24 hours with RSL3 
(late ferroptotic MCA205 cells), we observed that the late 
ferroptotic cells were effectively engulfed by BMDCs but 
the viable cells were not (figure 2B,C). Increasing the 
ratio of BMDCs to late ferroptotic MCA205 cells from 1:1 
to 1:5 increased the rate of engulfment proportionately 
(figure 2B,C).
In order to obtain a better insight into the func-
tional status of BMDCs, we evaluated the immunogenic 
Figure 1 Ferroptotic cell death induction in cancer MCA205 cells. (A) Ferroptotic cell death analysis by staining with Sytox 
Green (% of dead cells). Cell death was significantly reduced by ferroptosis inhibitors (DFO, Fer-1 and α-toc) whereas inhibitors 
of apoptosis (zVAD- fmk) and necroptosis (Nec- 1s) were ineffective. The following concentrations of inhibitors were used: 
25 µM zVAD- fmk, 20 µM Nec- 1s, 1 µM FER-1, 10 µM DFO and 100 µM α-toc. The values are the means±SEM and represent 
four independent experiments. Statistical significance was calculated by two- way ANOVA followed by Dunnett’s multiple 
comparisons test: ****p<0.0001. (B) Morphological analysis of ferroptotic MCA205 cells by fluorescence microscopy showing 
swelling and rounding of MCA205 cells undergoing ferroptosis. MCA205 cells were stained with propidium iodide (red) and 
Hoechst33342 (blue). The images were derived from online supplemental movies S1. (C) Characterization of ferroptotic MCA205 
cells by AFM revealing the formation of membrane protrusions (white arrows) on the surface of ferroptotic MCA205 cells. Each 
panel is divided into two images: left: 3D AFM image; right: whole cell 2D AFM image. (A–C) MCA205 cells were stimulated with 
2.5 µM RSL3. DFO, deferoxamine; Fer-1, ferrostatin-1; RSL3, RAS- selectivelethal 3; α-toc, α-tocopherol.
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characteristics of late ferroptotic cells in vitro (ie, after 
24 hours of RSL3 stimulation, figure 3A–E). For this, 
we compared BMDCs exposed to late ferroptotic cells 
to BMDCs exposed to viable cancer cells. For a positive 
control, we induced immunogenic apoptosis by treating 
MCA205 cells with MTX,10 22 and LPS was used as another 
positive control. Surprisingly, late ferroptotic cells did 
not induce a phenotypic maturation of BMDCs, as indi-
cated by the absence of surface upregulation of the 
costimulatory molecules CD11c+CD86+, CD11c+CD80+ 
and CD11c+MHCII+ (figure 3A,B) and levels of IL-6 
(figure 3D) when compared with BMDCs cocultured with 
viable cells. The nonimmunogenicity of late ferroptotic 
cancer cells was confirmed in vitro on another cancer cell 
line, murine glioma GL261 cells, which die ferroptoti-
cally after RSL3 stimulation (online supplemental figure 
S1A,B). RNAseq analysis revealed that unlike GL261 cells 
treated with MTX, a well- known chemotherapeutic that 
induces ICD,10 22 coculture of late ferroptotic glioma 
cells with BMDCs did not induce an immunogenic gene 
expression profile in the BMDCs (online supplemental 
figure S2).
Together, these in vitro results indicate that late ferro-
ptotic cancer cells that were treated with a GPX4 inhib-
itor for 24 hours are potent inducers of BMDC- mediated 
phagocytic clearance. However, our findings indicate that 
two different types of cancer cells (fibrosarcoma MCA205 
cells and glioma GL261 cells) undergoing late ferroptosis 
cannot induce an immunogenic signature in BMDCs.
Early ferroptotic cancer cells induce maturation of BMDCs
It is conceivable that the immunogenicity of dying cancer 
cells may vary significantly depending on the stage of cell 
death. Therefore, to assess the dependency of the immu-
nogenic properties of ferroptotic cancer cells on the 
cell- death stage, we cocultured BMDCs with cancer cells 
treated for 1 hour with RSL3, which leads to so- called early 
ferroptotic cell death. After 1 hour of RSL3 treatment, the 
cancer cells showed early signs of cell death. Less than 6% 
of the cancer cells were double positive for Annexin- V/
Sytox Blue staining (figure 2A), indicating that they were 
still in an early stage of ferroptosis. By coculturing BMDCs 
with untreated, viable MCA205 cells or with MCA205 cells 
treated for 1 hour with RSL3 (early ferroptotic MCA205 
Figure 2 Phagocytosis assay showing effective uptake of early ferroptotic cancer cells by BMDCs. (A) Ferroptotic cell death 
measured by flow cytometry of the MCA205 cells used in the phagocytosis assay shown in figure 2B,C. Quantification was 
done by Annexin- V (AnV) and Sytox Blue (Sytox) staining. The values are the means±SEM and represent four independent 
experiments. (B) Ferroptotic MCA205 cancer cells are efficiently engulfed by BMDCs. Of note, ferroptotic MCA205 cells are 
efficiently engulfed after 1 hour stimulation with RSL3 even in the absence of Annexin- V/Sytox Blue staining (figure 2A). MCA205 
cells were stimulated with RSL3 for 1 hour or 24 hours. Data represent mean values±SEM from four independent experiments. 
Statistical significance was calculated by two- way ANOVA followed by Tukey’s multiple comparisons test: **p<0.01, ***p<0.001, 
****p<0.0001. (C) The flow cytometry dot plots show the uptake of pHrodo- labeled ferroptotic cells by BMDCs (CD11c+pHrodo+ 
double positive cells). The rate of phagocytosis is proportionally increased by increasing the ratio of BMDCs: MCA205 (1:1 to 
1:5). BMDCs, bone- marrow derived dendritic cells; RSL3, RAS- selectivelethal 3.
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cells), we observed that the early ferroptotic cells were 
efficiently engulfed by BMDCs but the viable cells were 
not (figure 2B,C). Increasing the ratio of BMDCs to early 
ferroptotic MCA205 cells from 1:1 to 1:5 increased the 
rate of engulfment proportionately (figure 2B,C). Impor-
tantly, only 15% of the cell population were Annexin- V+/
Sytox Blue−, indicating that clearance of these early ferro-
ptotic cells probably occurs via mechanisms other than 
PS exposure.44–46 Furthermore, when we cocultured these 
early ferroptotic cancer cells with BMDCs for 24 hours, 
we observed that early ferroptotic cancer cells induced 
CD80, CD86 and MHCII expression in CD11c+ BMDCs 
(figure 3A,B,E). Importantly, the substantial surface 
expression of these molecules was very similar to that 
induced by MTX, a positive control, when BMDCs were 
cocultured with early ferroptotic cells (figure 3A,B). Of 
note, coculture with the same amount of cancer cells 
undergoing late ferroptosis did not alter the maturation 
status of the BMDCs (figure 3A,B). Moreover, ferroptotic 
MCA205 cells after 3 hours of RSL3 treatment were also 
able to induce intermediate levels of CD80, CD86 and 
MHCII expression in CD11c+ BMDCs (figure 3A,B). 
There is, indeed, an inverse correlation between the stage 
of ferroptotic cell death in MCA205 cells and maturation 
status of the BMDCs (figure 3C).
To gain a deeper understanding of the functional status 
of BMDCs, we measured the production of the proinflam-
matory cytokine, IL-6. We compared BMDCs exposed to 
early ferroptotic MCA205 cells with those exposed to live 
MCA205 cancer cells. We found that BMDCs exposed to 
early ferroptotic cancer cells displayed a distinctive and 
ratio- dependent pattern of functional activation charac-
terized by IL-6 production (figure 3D).
Early but not late ferroptotic cancer cells induce anti-
tumor immunogenicity in mice that results in an adaptive 
immune response
To test the ability of early ferroptotic cancer cells to acti-
vate the adaptive immune system, we took advantage of 
the well- accepted prophylactic tumor vaccination model 
in immunocompetent C57BL/6 J mice (figure 4A).7 40 47 
We immunized C57BL/6 J mice with early or late ferro-
ptotic MCA205 cells (figure 4B, online supplemental 
figure S3B) and injected the negative control mice with 
PBS or with accidental necrotic MCA205 cells (F/T).40 47 
The immunized mice were then challenged with viable 
MCA205 tumor cells. Protection against tumor growth at 
Figure 3 Ferroptotic cells induce maturation of bone- marrowderived dendritic cells (BMDCs) in a manner depending on the 
cell- death stage. (A) Representative flow cytometry dot plots demonstrating the gating and percentage of CD11c+MHCII+, 
CD11c+CD80+ and CD11c+CD86+ BMDCs cocultured in a 1:5 ratio with ferroptotic (RAS- selectivelethal 3 (RSL3) 1 hour, 3 hours, 
or 24 hours), untreated (viable), and mitoxantrone- treated (MTX) MCA205 cells. As a positive control BMDCs stimulated with 
lipopolysaccharide (LPS) were used. (B) Ferroptotic MCA205 cancer cells induce maturation of BMDCs in a manner that 
depends on the cell- death stage: early ferroptotic cells (after 1 hour or 3 hours of RSL3 stimulation) are more potent inducers of 
BMDCs maturation than late ferroptotic cells (after 24 hours of RSL3 stimulation). Notably, early ferroptotic cells (ie, after 1 hour 
of RSL3 stimulation) were as immunogenic as cancer cells treated with mitoxantrone (2 µM MTX, 24 hours), a positive control. 
BMDCs were cocultured with ferroptotic MCA205 cells in a 1:5 ratio. Dashed lines specify percentages of the CD11c+MHCII+, 
CD11c+CD80+ and CD11c+CD86+ populations, respectively, for BMDCs cocultured with viable MCA205 cells (control). BMDCs 
stimulated with LPS served as an additional positive control. Percentages of CD11c+MHCII+, CD11c+CD80+ and CD11c+CD86+ 
cells shown as mean values±SEM of four independent experiments for RSL3 1 hour, and seven independent experiments 
for other conditions. Two- way ANOVA was used to calculate the statistical significance: **p<0.01, ***p<0.001, ****p<0.0001. 
(C) Linear correlation of AnV+Sytox+ ferroptotic cells (figure 3E) and CD11c+MHCII+, CD11c+CD80+ or CD11c+CD86+ cells, 
respectively. (D) Absolute concentrations of IL-6 in cocultures of BMDCs with the respective target MCA205 cells at two 
different ratios (1:1, 1:5). LPS- treated BMDCs and coculture of BMDCs with MTX- treated MCA205 cells were used as a positive 
control. The values are the means±SEM of eight (for BMDCs alone, BMDCs cocultured with viable MCA205 cells, BMDCs 
cocultured with RSL3- treated MCA205 cells for 24 hours groups), seven (for BMDCs co- cultured with MTX- treated MCA205 
cells, BMDCs co- cultured with RSL3- treated MCA205 cells for 3 hour groups) and six (for BMDCs treated with LPS, BMDCs 
cocultured with RSL- treated MCA205 cells for 1 hour groups) independent measurements performed in duplicates. Statistical 
significance was calculated by a Mann- Whitney nonparametric t- test: *p<0.05, ***p<0.001. (E) Ferroptotic cell death measured 
by flow cytometry of the MCA205 cells used in the maturation assay shown in figure 3A–C.
G
eneeskunde - P






















8 Efimova I, et al. J Immunother Cancer 2020;8:e001369. doi:10.1136/jitc-2020-001369
Open access 
the challenge site was interpreted as a sign of successful 
priming of the adaptive immune system. Interestingly, 
mice immunized with late ferroptotic MCA205 cells 
(24 hours of RSL3 induction) remained significantly less 
tumour- free at the challenge site (figure 4B), indicating 
that late ferroptotic cells are not immunogenic in vivo, 
confirming our initial in vitro observations (figures 2B,C 
and 3A–E and online supplemental figure 2C–H). In 
contrast, mice immunized with early ferroptotic MCA205 
cells showed attenuation of the appearance of tumors 
at the challenge site (figure 4B), confirming the strong 
immunogenic potential of early ferroptotic cells seen in 
vitro (figure 3A–D). Notably, the mice vaccinated with 
late ferroptotic cells developed tumors very similar to 
mice vaccinated with F/T cells, which are known to be 
nonimmunogenic.22 40 48 It is noteworthy that early ferro-
ptotic cancer cells were significantly more immunogenic 
than accidental necrotic cells. This is in line with the 
immunogenicity of late ferroptotic cancer cells, but it 
was completely lost when the mice were vaccinated with 
half the number of cells, whereas the early ferroptotic 
cancer cells remained immunogenic (figure 4, online 
supplemental figure S3A,B). These results indicate that 
the immunogenicity of ferroptosis depends on the cell 
death stage: only early but not late ferroptotic cancer 
cells induced protection in the murine vaccination 
experiments.
To examine the role of the adaptive immune system, 
we determined whether vaccination of immune compro-
mised mice with early ferroptotic cancer cells would lead 
to protective immunity against challenge with viable 
cancer cells. For this, Rag-2- deficient mice were inocu-
lated with early ferroptotic cancer cells or with PBS and 
1 week later challenged with viable MCA205 cancer cells 
(figure 4A). Interestingly, the tumor- protective effect of 
early ferroptotic cancer cells was absent in Rag-2−/− mice 
and was comparable to the mice vaccinated with PBS 
(figure 4C). These data suggest that the adaptive immune 
system is required for induction of tumor protection by 
early ferroptotic cancer cells.
Immunogenicity of early ferroptosis is associated with time-
dependent ATP and HMGB1 release
One of the main characteristics of the immunoge-
nicity of cancer cells undergoing ICD is the spatiotem-
porally coordinated emission of DAMPs (eg, ATP and 
HMGB1), which is beneficial in anticancer therapy owing 
to the interaction of these DAMPs with the immune 
system.8 39 49–52 As ATP is one of the most critical DAMPs, 
we first analyzed the kinetics of the ATP release induced 
by RSL3 in MCA205 cells. We noticed that ATP release 
temporally followed the cell death process (figure 5A,B). 
After 3 hours of RSL3 treatment, ferroptotic cancer cells 
started releasing ATP until 6 hours but by 24 hours, all 
released ATP was depleted (figure 5B). Of note, the 
pattern of HMGB1 release, another well- known DAMP, 
from ferroptotic cancer cells, was different from that of 
ATP release. The maximal level of HMGB1 release was 
reached only after 24 hours of stimulation with RSL3 
(figure 5C,D), which corresponds to the late ferroptotic 
stage. The levels of HMGB1 in the supernatant from the 
early ferroptotic cells were not statistically different from 
the level in viable cancer cells (figure 5C).
Next, we performed the cell death recovery experi-
ment to better mimic in vitro coculture and prophylactic 
vaccination experiments in which the dead cells are 
detached and washed with PBS before their use in these 
experiments. Even after removing the RSL3 stimulus, the 
cells continued to undergo ferroptosis (figure 6A). To 
further confirm this hypothesis, we measured ATP and 
HMGB1 concentrations during coculture of early and 
Figure 4 Early ferroptotic cells are immunogenic in vivo. 
(A) The in vivo prophylactic tumor vaccination model. The 
MCA205 cells used for immunization were stimulated with 
RSL3 for 3 hours or 24 hours and resuspended in PBS before 
injection. (B) Kaplan- Meier curve of the progression of tumor 
development over time. C57BL/6 J mice were vaccinated 
with 5 × 105 MCA205 cells treated with RSL3. Then 1 week 
late the mice were challenged with viable MCA205 cells. 
MCA205 cells induced by RSL3 for 3 hours triggered an 
anti- tumor immune response in mice immunized with 5 × 105 
cells. Negative control mice were injected with PBS or with 
MCA205 cells undergoing accidental necrosis (F/T, freeze and 
thaw group). (C) Kaplan–Meier curve of the progression of 
tumor development over time. Rag-2-/- mice were vaccinated 
with 5 × 105 MCA205 cells treated with RSL3 for 3 hours. after 
1 week, the mice were challenged with viable MCA205 cells. 
No antitumor immune response was triggered in mice Rag-
2−/− immunized with ferroptotic MCA205 cells. The statistical 
differences were calculated by a log- rank (Mantel- Cox) test. 
Survival curves comparison: *p<0.05, ****p<0.0001. PBS, 
phosphate- buffered saline; RSL3, RAS- selectivelethal 3.
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late ferroptotic cancer cells with BMDCs (figure 6B), 
which most accurately reflects the actual situation occur-
ring in vitro and in vivo. In cocultures of BMDCs with 
early ferroptotic cells (1 hour or 3 hours with RSL3), ATP 
concentration was 3.5 and 2.8 times higher, respectively, 
than in cocultures with late ferroptotic cells (24 hours 
with RSL3) (figure 6C). ATP levels of the coculture of 
BMDCs and cancer cells treated for 24 hours (late ferro-
ptotic cells) were similar to those in BMDCs cocultures 
with viable cells (figure 6C). Surprisingly, we observed 
that the level of HMGB1 was at its maximum in the cocul-
ture of BMDCs with early ferroptotic cancer cells (1 hour 
or 3 hours with RSL3, figure 6D). The HMGB1 level was 
not statistically different in the cocultures of BMDCs with 
the late ferroptotic cells (24 hours with RSL3) from that 
in the control groups (ie, BMDCs alone or BMDCs cocul-
tured with viable cancer cells) (figure 6D). All these data 
suggest a potential role of ATP and HMGB1 in the immu-
nogenicity of early ferroptotic cancer cells.
In the light of the in vitro and in vivo data, we hypothe-
size that ATP along with HMGB1 might be crucial for the 
immunogenicity of early ferroptosis. Indeed, it has been 
shown that ATP release by cells undergoing immuno-
genic apoptosis is one of the major hallmarks of ICD.3 8 50 
To verify this hypothesis in vivo, we used the strategy of 
modulating the function of extracellular ATP by blocking 
purinergic receptors with the 2′,3′-dialdehyde deriva-
tive of ATP ('oxidized ATP', oxiATP), which inhibits the 
P2X7 subclass of purinergic receptors.
9 38 50 Blockade of 
purinergic receptors in early ferroptotic MCA205 cells 
(3 hours of RSL3 induction) significantly abolished their 
ability to protect the host against a lethal rechallenge with 
viable MCA205 cells (online supplemental figure S3C). 
Taken together, all these results underscore the cardinal 
contribution of ATP as one of the potential DAMPs in 
the immune response elicited by early ferroptotic cancer 
cells and underline the immunogenic potential of early 
ferroptotic cells.
Figure 5 Release of HMGB1 and ATP from ferroptotic cancer cells. (A) Cell death progression in cancer MCA205 cells on 
stimulation with RSL3 measured by Sytox Green fluorescence. Pool of three independent experiments. (B) Time- dependent ATP 
release from ferroptotic cancer MCA205 cells stimulated with RSL3. Note that the peak of ATP release corresponds to 6 hours 
of RSL3 stimulation but for 24 hours of stimulation ATP release is minimal. The values are the means±SEM of four independent 
measurements performed in triplicates. Two- way ANOVA was used to calculate the statistical significance: ***p<0.001, 
****p<0.0001. (C) Release of HMBG1 from ferroptotic MCA205 cancer cells stimulated with RSL3. The peak of HMGB1 release 
was at 24 hours of ferroptosis induction with RSL3. This is in reverse to the release of ATP: release of HMGB1 was minimal for 
early ferroptotic time- points (1 and 3 hours). The values are the means±SEM of four independent measurements performed in 
duplicates. One- way ANOVA with Tukey’s multiple comparison test was used to calculate the statistical significance: *p<0.05, 
****p<0.0001. (D) Ferroptotic cell death measured by flow cytometry of the MCA205 cells used for HMGB1 release. The values 
are the means±SEM of four independent measurements performed in duplicates. HMGB1,high- mobility group box 1; MTX, 
mitoxantrone; RSL3, RAS- selective lethal 3.
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DISCUSSION
ICD is a finely regulated process through which dying 
cells can stimulate the adaptive immune system. Apop-
totic and necroptotic ICD modalities have been exten-
sively described and characterized22 53 54 but no conclusive 
evidence is available about the immunogenicity of ferro-
ptosis.34 Here, we demonstrate for the first time that ferro-
ptosis induces ICD both in vitro and in vivo (figure 7). We 
show that the ferroptotic stage of dying cells is crucial in 
determining their immunostimulatory capacity and that 
several DAMPs, including ATP and HMGB1, might be 
necessary for promoting ferroptotic ICD.
The first discovery we made is that only early dying 
ferroptotic cells can induce ICD efficiently in vitro and in 
vivo. We noticed that, in vitro, early ferroptotic cells were 
engulfed by BMDCs, but to a lesser extent than late ferro-
ptotic cells. When we cocultured BMDCs with ferroptotic 
cells, we noted an inverse relationship between how long 
tumor cells were treated with RSL3 before coculture and 
the extent of BMDCs maturation (figure 3C). MCA205 
cells pretreated for 1 hour increased the expression of all 
BMDCs maturation markers and IL-6 levels to the same 
or even greater extent than the bone fide ICD inducer 
MTX, which was used as a positive control (figure 3A–D). 
Tumor cells treated for 3 hours were somewhat less effec-
tive than cells treated for 1 hour with RSL3, while no 
BMDCs phenotypic maturation was observed when late 
Figure 6 Early but not late ferroptotic cancer cells induce immunogenic cell death in vitro. (A) Cell- death recovery was 
measured by Sytox Green fluorescence in cancer MCA205 cells on stimulation with RSL3. After 1 hour, 3 hours and 6 hours of 
RSL3 stimulation, the cells were washed in PBS and reseeded in fresh culture medium (without RSL3) and cultured further for 
23 hours, 21 hours or 18 hours, respectively, to give a total culture time. (B) Schematic representation of the measurement of 
ATP and HMGB1 release in the coculture of BMDCs with ferroptotic MCA205 cells shown in figure 6C,D. Viable or dying cancer 
MCA205 cells (induced with either RSL3 or MTX as positive controls) were harvested and cocultured with BMDCs for 3 hours 
(for ATP) or 24 hours (for HMGB1). Next, the supernatants were collected and analyzed for ATP using CellTiter- Glo Luminescent 
Cell Viability Assay (Promega) and for HMGB1 with ELISA kit (IBL- Hamburg). (C) The concentration of ATP in the coculture 
of BMDCs with ferroptotic MCA205 cells after 3 hours of coincubation. The values are the means±SEM of four independent 
measurements performed in triplicates. Two- way ANOVA was used to calculate the statistical significance (*p<0.05, **p<0.01). 
(D) The concentration of HMGB1 in the coculture of BMDCs with ferroptotic MCA205 cells after 24 hours. The values are the 
means±SEM of three independent measurements performed in duplicates. One- way ANOVA with Tukey’s multiple comparison 
test was used to calculate the statistical significance: ****p<0.0001. For positive control, BMDCs were cocultured with 
MCA205 cells killed by MTX (2 µM, 24 hours). Activation and maturation profiles of BMDCs from these experiments are shown 
in figure 3A–C. BMDCs,bone- marrow derived dendritic cells; HMGB1, high- mobility group box 1; MTX, mitoxantrone; PBS, 
phosphate- buffered saline; RSL3, RAS- selectivelethal 3.
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ferroptotic MCA205 cells were used (24 hours of RSL3 
treatment).
Our results show that early dying cells, which are char-
acterized by an intact membrane, are more immunogenic 
than late- dying cells, which are spilling out all their intra-
cellular material. Studies on immunogenic apoptosis and 
necroptosis have disclosed that the immune stimulation 
is a tightly regulated mechanism, with each stimulus, 
i.e., DAMP, activated at a precise moment and that the 
activation of all DAMPs in a specific sequence executes 
effective activation of the immune system.2 7 Depending 
on the stimulus, a generic chemotherapeutic agent exerts 
a cytotoxic effect that immediately determines whether 
cell death will be immunogenic, silent or tolerogenic. 
Indeed, every cell death program enacts the exposure 
of different ‘eat me’ and ‘don’t eat me’ signals, which, 
combined with different receptors that either promote 
or inhibit engulfment and, thus regulate uptake of the 
cells.55 For instance, PS externalization on the outer cell 
surface is one of the best- known crucial events in the 
recognition and elimination of dying cells. In apoptotic 
cells, it represents a point of no return and flags apop-
totic cells to alert professional antigen presenting cells 
(APCs), such as BMDCs, to clear them.56–58 Similarly, in 
necroptotic cells, PS promotes their clearance. PS- pos-
itive necroptotic cells can be revived and start clonal 
growth.26 59–61 Interestingly, we found that early ferro-
ptotic cancer cells were efficiently cleared by BMDCs 
but remained largely negative for Annexin- V staining 
(figure 2A,B), a marker often used to detect PS on the 
cell surface of dying cells.62 63 Thus, it is conceivable that 
other ‘eat me’ signals besides PS could be involved in the 
clearance of early ferroptotic cells. For instance, during 
immunogenic apoptosis, translocation of CRT to the 
outer cellular membrane (Ecto- CRT) is usually the first 
‘eat me’ signal emitted, happening even before PS expo-
sure.10 64 Ecto- CRT on a membrane on which no PS has 
been exposed has been proven to provide the switch to a 
cognate immune response by APCs such as macrophages 
and dendritic cells.10 64–67 Ecto- CRT could be the missing 
Figure 7 Graphical abstract—timespan of immunogenicity of ferroptotic cancer cell death. After receiving ferroptotic stimuli, 
cancer cells start to undergo cell death (Phase 0) and release DAMPs (eg, ATP and HMGB1). After 3 hours of ferroptosis 
induction, cancer cells are in phase I, which is the early ferroptotic cell death stage, where the highest levels of ATP and 
HMGB1 are reached. At this time point, early ferroptotic cancer cells are engulfed by BMDCs and promote their activation and 
maturation, as evidenced by analyses of their phenotypic markers (MHCII, CD80, and CD86) and the pro- inflammatory cytokine 
IL-6. In addition, if early ferroptotic cells in Phase I are injected into mice, they lead to protective immunity in the mouse tumor 
prophylactic vaccination model if the adaptive immune system is intact. In the late ferroptotic phase II, cancer cells are no 
longer immunogenic. Because all the supernatants (SN) from the late ferroptotic cancer cells (treated with RSL3 for 24 hours) are 
removed and no DAMPs (ie, HMGB1, ATP) are present anymore, which are required for their immunogenicity. Notably, although 
late ferroptotic cells were engulfed by BMDCs, they failed to induce BMDC phenotypic activation and maturation in vitro or to 
induce an effective antitumor immune response. It is crucial that phase I ferroptotic cell death occurs in the presence of antigen- 
presenting cells and should preferably proceed in vivo. During that stage (ie, phase I), most of ATP and HMGB1 and possibly 
other DAMPs are released or reaching the maximal levels, thereby creating the best adjuvanticity effect of early ferroptotic 
cancer cells. These data show that the stage of cell death is a key aspect of the immunogenicity of ferroptotic cancer cells and 
demonstrate that ATP and HMGB1 released after ferroptosis induction may act as immunogenic signals. BMDCs,bone- marrow 
derived dendritic cells; DAMPs, damage- associated molecularpatterns; HMGB1, high- mobility group box 1.
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piece that would explain why early ferroptotic cells can 
be significantly engulfed by BMDCs, while viable cells are 
not (figure 2B,C), even if they share the lack of exposed 
PS (figure 2A).
Notably, it has been shown that the stage of apop-
totic cell death is not important for its immunogenicity. 
Indeed, no correlation was found between the immuno-
genicity of early dying (Annexin- V+/PI–) and late- dying 
(Annexin- V+/PI+) apoptotic cells. This means that both 
early10 68 69 and late14 70 apoptotic cells trigger ICD both 
in vitro and in vivo. This is at odds with our finding that 
immunogenicity of ferroptosis depends on the cell- death 
stage.
Driven by these results and in order to choose the 
best stage of cell death for in vitro and in vivo vaccina-
tion, we simulated in vitro what happens to tumor cells 
after the ferroptotic stimulus is removed. In the in vitro 
experimental setup, we simulated the in vivo prophy-
lactic vaccination and BMDCs coculture conditions by 
washing the dying cells in PBS before injection into mice. 
We observed that cells treated with RSL3 continue to die 
after reseeding in fresh medium without the inducer 
(figure 6A). We were looking for a relationship between 
the immunostimulatory effect and cell death. The amount 
of cell death after 1 hour of treatment with RSL3 was not 
enough for the cells to be used in the in vivo experiments. 
Therefore, we compared the in vivo effect of ferroptotic 
cells treated for 3 hours with those treated for 24 hours. 
The results confirmed the abovementioned trend: vacci-
nation experiments showed significant activation of the 
adaptive immune system by injection of early ferroptotic 
cells (3 hour stimulation) but no effect of late ferroptotic 
cells (24 hours stimulation). This was confirmed by using 
immune- deficient (Rag-2−/−) mice, in which the immu-
nogenicity of early ferroptotic cancer cells was absent 
(figure 4C). The role of the adaptive immune system in 
vaccination with apoptotic14 71 and necroptotic24 72 cells 
has been previously shown.
Even if we find an explanation for the immunogenicity 
of early ferroptotic cells, the lack of immunogenicity of 
the late death stage remains, in a way, counterintuitive 
and challenges the current concept of the high immu-
nogenic potential of cells in the later stages of cell death. 
Indeed, it is commonly believed that the release of the 
complete intracellular content, including a large amount 
of DAMPs (ie, inflammatory stimuli), occurs mainly in 
the later stages of cell death when the plasma membrane 
ruptures, and so the later stages represent the best way 
to induce an antigen- specific adaptive immune response 
mediated by CD8+ T cells.73–75 However, our in vivo vacci-
nation experiments showed that ferroptotic cells in the 
late stage of death, like accidental necrotic cells killed 
by freezing and thawing, were unable to protect mice 
from tumor development at the challenge site. This chal-
lenges the notion that for local inflammation and infiltra-
tion, the massive release of intracellular content during 
late cell- death stages is always proinflammatory and 
immunogenic. The nonimmunogenicity of cancer cells 
undergoing accidental necrosis has been described,14 22 73 
and in this study, we show that ferroptotic cancer cells are 
immunogenic in the early stages of cell death.
As mentioned above, DAMPs release during ICD is not 
a continuum, and exposure or secretion of ‘eat me’ and 
‘find me’ signals probably does not persist for the dura-
tion needed for cells to die. Recently, it has been shown 
that ferroptotic cells release HMGB1.76 77 In contrast, 
we show here that several DAMPs, including ATP and 
HMGB1, are released from ferroptotic cancer cells in 
a strict time- dependent manner. In other words, with 
sequential presentation of DAMPs, they can coexist at the 
same stage, and synergy of their signals will lead to devel-
opment of an effective immune response.65 Our data 
indicate that the process of cell death from its very early 
stages would occur in situ (figure 7), which will enable 
the release of the DAMPs in a consequent manner during 
the cell death process, leading to the induction of effec-
tive immune responses. Thus, from a practical point of 
view, it could be best to perform vaccination with cells 
in the middle of the process of DAMPs release so that 
early, middle and late danger signals might occur in situ 
(figure 7).
Key DAMPs might be depleted in cancer cells in the 
latest stage of cell death. Furthermore, the experimental 
setting requires that dying cancer cells are washed before 
injection in mice or testing for BMDC studies, so soluble 
DAMPs already secreted in the medium will be lost. If 
those missing DAMPs are important in the activation of 
adaptive immunity, the result would be an immunologi-
cally silent cell death or even immune suppression. There-
fore, the time dependency of ICD in terms of DAMPs 
activation and presentation to the immune system effec-
tors, in contrast to the mere spilling of all signals, might 
explain the lack of protection against tumor development 
in mice when late ferroptotic cells are used as a vaccine.
Together with CRT, HMGB-1 and ATP represent two 
limiting features of the immunogenicity of apoptosis 
and necroptosis.11 22 50 78 It has been demonstrated that 
active secretion of ATP and passive release of HMGB1 
are crucial for the generation of an adaptive immune 
response to apoptotic ICD,50 while necroptotic immu-
nogenic cells can passively release this crucial DAMP.22 23 
Here, we show that RSL3 promotes a perimortem, time- 
dependent ATP and HMGB1 release, most probably due 
to rupture of the cell membrane, which is maximal when 
cells are treated with RSL3 for up to 6 hours for ATP and 
up to 24 hours for HMGB1. The kinetics of ATP and 
HMGB1 release overlaps that of cell death (figure 5A–D), 
and thus the cells are most likely not releasing ATP and 
HMGB1 actively. Even if we did not observe premortem 
ATP secretion, the interesting point is that after 24 hours, 
ATP was completely degraded (figure 5B). This is in line 
with previous reports on ATP exhaustion after cell death 
stimulation for a long time.22 79 80 So, to assess whether 
the lack of ATP and HMGB1 explains the inability of late 
ferroptotic cells to activate the adaptive immune system, 
we measured their levels in the supernatants of BMDCs 
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cocultured with ferroptotic MCA205 cells treated with 
RSL3 for different times. Importantly, the levels of ATP 
and HMGB1 were maximal when the cells were treated 
for a short time and therefore in the early stages of ferro-
ptosis (figure 6C,D). Additionally, if we blocked the 
cognate ATP P2X7 purinergic receptors in vivo, 3- hour 
ferroptotic cells were not protective in mice, demon-
strating their inability to trigger an adaptive immune 
response. All these data together suggest that passive 
release of ATP and possibly also HMGB1 are essential 
for the immunogenicity of ferroptosis. These results also 
explain why late stages of ferroptotic cancer cell death are 
not immunogenic. Moreover, it is important to empha-
size that the nonimmunogenic nature of late ferroptotic 
cancer cells is not tumor- type specific. As RNA- seq anal-
ysis shows, the gene expression profile of BMDCs is not 
significantly affected by 24- hour RSL3- treated GL261 
cells compared with MTX treatment, pointing to absence 
of significant immunogenic potential in late ferroptotic 
cancer cells (online supplemental figure S2).
In addition, it is important to stress that an adaptive 
immune response depends on the recognition of different 
tumor associated antigens (TAA). Thus, ICD should have 
a balanced combination of adjuvanticity (effects related 
to DAMPs) and antigenicity (attributed mainly to tumor 
antigens) to induce efficient antitumor immunity. In this 
regard, it was recently illustrated that the strong expres-
sion of the immunodominant TAA, AH1, was indispens-
able for the immunogenicity of apoptotic cancer cells, 
whereas necroptotic cancer cells could also engage other 
neoepitopes.72 This finding highlights the importance 
of the immunodominant TAA and demonstrates its anti-
genic contribution to ICD, which is required, in addition 
to DAMPs, for induction of efficient antitumor immunity. 
Taken together, the results suggest that early and late 
ferroptotic cancer cells could have different patterns of 
TAA and neoantigens that contribute to their antigenicity 
and thus their immunogenicity and antitumor effect. This 
is a challenging area for future research.
Taking these data together, we have shown that the 
exhaustion of crucial effector DAMPs could explain the 
cell- death stage dependency of ferroptotic cells. Late 
ferroptotic cells used either for vaccination experiments 
or for coculture with BMDCs have already lost some key 
DAMPs, such as ATP and HMGB1, and so late- stage ferro-
ptotic cells do not present all the necessary elements 
needed to promote the stimulation of the immune system 
and cannot trigger a vaccination- like effect (figure 7). We 
conclude that the stage of cell death is a key aspect of 
the immunogenicity of ferroptotic cancer cells and their 
effect on antitumor immunity. Further studies are needed 
to comprehend its molecular mechanism of action 
fully and determine whether other DAMPs, including 
Ecto- CRT and IFNs, are critical in this process.
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